Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Inovio Stock Sank Today

By Keith Speights - Dec 28, 2020 at 4:05PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Analysts have very different takes on the early-stage results for the company's COVID-19 vaccine candidate.

What happened

Shares of Inovio Pharmaceuticals ( INO -6.66% ) were sinking 6.6% as of 3:47 p.m. EST on Monday. The decline came after analysts gave mixed reviews to the biotech's phase 1 data from COVID-19 vaccine candidate INO-4800. These early-stage results were published in The Lancet's online clinical journal EClinicalMedicine on Dec. 24.

So what

Piper Sandler analyst Christopher Raymond views INO-4800 as an "also-ran" compared to leaders in the coronavirus vaccine race. He remains highly skeptical of Inovio's prospects with its COVID-19 vaccine candidate.

Scientist holding vaccine vial with syringe and needle

Image source: Getty Images.

Cantor Fitzgerald analyst Charles Duncan thought that Inovio's phase 1 results for INO-4800 didn't show as much potency as other coronavirus vaccines. He wrote to investors that it's possible that INO-4800 could hold potential as a third-generation or booster COVID vaccine. But Duncan thinks the jury is still out on those prospects.

On the other hand, H.C. Wainwright analyst Raghuram Selvaraju saw the early-stage data for INO-4800 as "very promising." Selvaraju wrote to investors that Inovio's experimental coronavirus vaccine produced immune responses in all vaccinated participants and demonstrated "excellent safety and tolerability."

Which analyst's view is right? It remains to be seen. However, INO-4800 will need to achieve exceptionally high efficacy in late-stage testing to be competitive against the COVID-19 vaccines from Pfizer and Moderna that have already won U.S. Emergency Use Authorization.

Now what

Inovio's shares have fallen nearly 70% over the last six months. The key to a rebound for the biotech stock is for INO-4800 to deliver unmistakably positive results that set it apart from other vaccines. Inovio is currently conducting phase 2 studies of the vaccine and hopes to advance it into late-stage testing in 2021.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
$6.17 (-6.66%) $0.44
Pfizer Inc. Stock Quote
Pfizer Inc.
$54.27 (2.32%) $1.23
Moderna, Inc. Stock Quote
Moderna, Inc.
$306.72 (1.74%) $5.23

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/05/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.